164 related articles for article (PubMed ID: 19291396)
1. Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach.
Sun Y; Urquidi V; Goodison S
Breast Cancer Res Treat; 2010 Feb; 119(3):593-9. PubMed ID: 19291396
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
3. Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer--the INNODIAG study.
Kempowsky-Hamon T; Valle C; Lacroix-Triki M; Hedjazi L; Trouilh L; Lamarre S; Labourdette D; Roger L; Mhamdi L; Dalenc F; Filleron T; Favre G; François JM; Le Lann MV; Anton-Leberre V
BMC Med Genomics; 2015 Feb; 8():3. PubMed ID: 25888889
[TBL] [Abstract][Full Text] [Related]
4. Stable Gene Signature Selection for Prediction of Breast Cancer Recurrence Using Joint Mutual Information.
Sehhati M; Mehridehnavi A; Rabbani H; Pourhossein M
IEEE/ACM Trans Comput Biol Bioinform; 2015; 12(6):1440-8. PubMed ID: 26671813
[TBL] [Abstract][Full Text] [Related]
5. EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.
Buechler SA; Gökmen-Polar Y; Badve SS
Clin Breast Cancer; 2019 Feb; 19(1):17-26.e8. PubMed ID: 30097312
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.
Cai H; Li X; Li J; Ao L; Yan H; Tong M; Guan Q; Li M; Guo Z
Oncotarget; 2015 Dec; 6(42):44593-608. PubMed ID: 26527319
[TBL] [Abstract][Full Text] [Related]
7. [Gene signatures for breast cancer, clinical utility and therapeutic applications].
Vargas-Aguilar VM; Arroyo-Alvarez K
Rev Med Inst Mex Seguro Soc; 2018; 56(2):180-185. PubMed ID: 29906029
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a lipogenic genes panel for diagnosis and recurrence of colorectal cancer.
Gharib E; Nasrinasrabadi P; Zali MR
PLoS One; 2020; 15(3):e0229864. PubMed ID: 32155177
[TBL] [Abstract][Full Text] [Related]
9. A potential prognostic prediction model of colon adenocarcinoma with recurrence based on prognostic lncRNA signatures.
Jin L; Li C; Liu T; Wang L
Hum Genomics; 2020 Jun; 14(1):24. PubMed ID: 32522293
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
[TBL] [Abstract][Full Text] [Related]
11. A Novel 18-Marker Panel Predicting Clinical Outcome in Breast Cancer.
Biermann J; Nemes S; Parris TZ; Engqvist H; Rönnerman EW; Forssell-Aronsson E; Steineck G; Karlsson P; Helou K
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1619-1628. PubMed ID: 28877888
[No Abstract] [Full Text] [Related]
12. Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials.
Theilhaber J; Chiron M; Dreymann J; Bergstrom D; Pollard J
BMC Bioinformatics; 2020 Jul; 21(1):333. PubMed ID: 32711453
[TBL] [Abstract][Full Text] [Related]
13. Gene signatures and prognostic analyses of the Tob/BTG pituitary tumor-transforming gene (PTTG) family in clinical breast cancer patients.
Wu CC; Ekanem TI; Phan NN; Loan DTT; Hou SY; Lee KH; Wang CY
Int J Med Sci; 2020; 17(18):3112-3124. PubMed ID: 33173433
[TBL] [Abstract][Full Text] [Related]
14. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
16. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
[TBL] [Abstract][Full Text] [Related]
17. Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer.
Karlsson E; Delle U; Danielsson A; Olsson B; Abel F; Karlsson P; Helou K
BMC Cancer; 2008 Sep; 8():254. PubMed ID: 18778486
[TBL] [Abstract][Full Text] [Related]
18. Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures.
Huang CC; Tu SH; Lien HH; Huang CS; Huang CJ; Lai LC; Tsai MH; Chuang EY
Breast Cancer Res Treat; 2014 Sep; 147(2):353-70. PubMed ID: 25158930
[TBL] [Abstract][Full Text] [Related]
19. A disease annotation study of gene signatures in a breast cancer microarray dataset.
Gypas F; Bei ES; Zervakis M; Sfakianakis S
Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():5551-4. PubMed ID: 22255596
[TBL] [Abstract][Full Text] [Related]
20. Identification of key genes relevant to the prognosis of ER-positive and ER-negative breast cancer based on a prognostic prediction system.
Xiao B; Hang J; Lei T; He Y; Kuang Z; Wang L; Chen L; He J; Zhang W; Liao Y; Sun Z; Li L
Mol Biol Rep; 2019 Apr; 46(2):2111-2119. PubMed ID: 30888555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
